Integrin-EGFR interaction regulates anoikis resistance in colon cancer cells

• Published in: Apoptosis (London) 2019-12, Vol.24 (11-12), p.958-971
• Main Authors: Guha, Deblina, Saha, Taniya, Bose, Sayantan, Chakraborty, Sreeparna, Dhar, Subhanki, Khan, Poulami, Adhikary, Arghya, Das, Tanya, Sa, Gaurisankar
• Format: Article
• Language: English
• Subjects: Ablation; AKT protein; Anoikis; Biochemistry; Biomedical and Life Sciences; Biomedicine; Body fluids; Cancer; Cancer cells; Cancer Research; Caspase-3; CD44 antigen; Cell Biology; Colon; Colon cancer; Colorectal cancer; Drug resistance; Epidermal growth factor receptors; Epithelial cells; Integrins; Intestine; MDR1 protein; Metastases; Oct-4 protein; Oncology; Organs; P-Glycoprotein; Pluripotency; Stem cells; Virology
• ISSN: 1360-8185; 1573-675X
• DOI: 10.1007/s10495-019-01573-5

Anoikis resistance is an essential property of cancer cells that allow the extra-cellular matrix-detached cells to survive in a suspended state in body fluid in order to metastasize and invade to distant organs. It is known that integrins play an important role in anoikis resistance, but detailed mechanisms are not well understood. Here we report that highly metastatic colon cancer cells showed a higher degree of anoikis resistance than the normal intestinal epithelial cells. These anoikis-resistant cancer cells express high-levels of integrin-α2, β1, and activated EGFR in the anchorage-independent state than the anchorage-dependent state. In contrast, normal intestinal epithelial cells failed to elevate these proteins. Interestingly, a higher co-association of EGFR with integrin-α2β1/-α5β1 was observed on the surface of anoikis-resistant cells. Thus, in the absence of extra-cellular matrix, integrins in association with EGFR activates downstream effectors ERK and AKT and suppress Caspase-3 activation to induce anoikis resistance as was confirmed from the gene-ablation and pharmacological inhibitor studies. Interestingly, these anoikis-resistant cancer cells express high-level of cancer stem cell signatures (CD24, CD44, CD133, EpCAM) and pluripotent stem cell markers (OCT-4, SOX-2, Nanog) as well as drug-resistant pumps (ABCG2, MDR1, MRP1). Altogether, our findings unravel the interplay between integrin-α2β1/-α5β1 and EGFR in anoikis resistance and suggest that the resistant cells are cancer initiating or cancer stem cells, which may serve as a promising target to combat metastasis of cancer.